SRD5A3-Congenital Disorder of Glycosylation (SRD5A3-CDG): A Comprehensive Disease Characterization Report

Category: Mendelian (autosomal recessive inborn error of metabolism) Compiled: 2026-09-01 | Evidence base: primary literature (PMIDs cited inline)

Summary

SRD5A3-Congenital Disorder of Glycosylation (SRD5A3-CDG; OMIM #612379; CDG type Iq; Orphanet ORPHA:79320) is a rare autosomal recessive inborn error of metabolism caused by biallelic loss-of-function variants in SRD5A3 (steroid 5α-reductase type 3; chromosome 4q12; HGNC:24420; OMIM 611715). The gene encodes polyprenol reductase, the enzyme that catalyzes the final, committed step of dolichol biosynthesis — reduction of the α-isoprene unit of polyprenol to form dolichol (PMID: 20637498). Because dolichol is the obligate lipid carrier for the dolichol-linked oligosaccharide (LLO) precursor of protein N-glycosylation, and also anchors glycans used in O-/C-mannosylation and glycosylphosphatidylinositol (GPI) anchor biosynthesis, enzyme deficiency produces a CDG type I* biochemical defect (hypoglycosylation of nascent glycoproteins) that branches to affect multiple glycosylation pathways at the endoplasmic reticulum (ER) membrane.

Clinically, SRD5A3-CDG is a congenital multisystem neuro-ophthalmologic-dermatologic disorder. Its consistent core features are intellectual disability/psychomotor delay, muscular hypotonia, cerebellar ataxia with cerebellar hypoplasia/atrophy, and a characteristic ocular spectrum (congenital nystagmus, optic disc pallor/optic atrophy, early-onset retinal dystrophy, ocular coloboma, cataract), frequently accompanied by ichthyosiform skin/chronic dermatitis. The historically separate Kahrizi syndrome (OMIM 612713: intellectual disability, coloboma, cataract, kyphosis) is allelic — indeed the same disorder (PMID: 20700148). Adult-onset/progressive features include kyphosis/scoliosis, retinitis pigmentosa, and cataracts (PMID: 27480077).

The disorder is ultrarare, with roughly 60 cases reported worldwide and approximately 23 distinct pathogenic variants described as of 2022. Diagnosis relies on exome/genome sequencing (including intragenic copy-number analysis) supported by a CDG-I serum transferrin pattern and biochemical demonstration of an elevated polyprenol/dolichol ratio. No disease-modifying therapy exists; management is symptomatic and multidisciplinary. Repurposing of the HMG-CoA reductase inhibitor atorvastatin and dietary dolichol supplementation remain experimental. This report synthesizes eight confirmed findings across 35 reviewed papers to populate the disease knowledge-base template.

Key Findings

Finding 1 — Genetic cause: biallelic loss-of-function SRD5A3 variants encoding polyprenol reductase

SRD5A3 (chromosome 4q12; HGNC:24420; OMIM 611715) encodes polyprenol reductase, which reduces the α-isoprene unit of polyprenol to form dolichol. Dolichol is the obligate lipid carrier for the dolichol-linked oligosaccharide precursor used in protein N-glycosylation, O-/C-mannosylation, and GPI-anchor synthesis. Biallelic pathogenic variants cause SRD5A3-CDG (a CDG type I disorder; OMIM #612379), inherited in an autosomal recessive manner. The seminal functional study established both gene function and disease causation: "We found that SRD5A3 is necessary for the reduction of the alpha-isoprene unit of polyprenols to form dolichols, required for synthesis of dolichol-linked monosaccharides, and the oligosaccharide precursor used for N-glycosylation"* (PMID: 20637498).

Notably, the same study observed residual dolichol in enzyme-depleted cells: "The presence of residual dolichol in cells depleted for this enzyme suggests the existence of an unexpected alternative pathway for dolichol de novo biosynthesis" (PMID: 20637498). This alternative/"detour" pathway — recently shown to be evolutionarily conserved in budding yeast (PMID: 42201967) — explains why patients retain partial glycosylation capacity despite null variants and likely accounts for survival compatible with life in this disorder.

Finding 2 — Core clinical phenotype: neurodevelopmental, ophthalmologic, cerebellar, and cutaneous involvement

Across independent patient cohorts, SRD5A3-CDG presents a recognizable multisystem picture: intellectual disability/psychomotor delay, muscular hypotonia, cerebellar ataxia with cerebellar hypoplasia/atrophy, congenital nystagmus, optic disc pallor/optic atrophy, early-onset retinal dystrophy, ocular coloboma, cataract, and ichthyosiform skin/chronic dermatitis. A concise clinical summary describes "a severe metabolic disease manifesting as muscle hypotonia, developmental delay, cerebellar ataxia and ocular symptoms; typically, nystagmus and optic disc pallor" (PMID: 31638560).

The ocular phenotype is a prominent and often presenting feature, with "early-onset retinal dystrophy as a primary manifestation" (PMID: 28253385). The allelic Kahrizi syndrome highlights the coloboma-cataract-kyphosis axis: "a novel syndrome consisting of mental retardation, coloboma, cataract and kyphosis (Kahrizi syndrome, OMIM 612713)" (PMID: 20700148). Phenotypic diversity is real: monozygotic twins have been reported with early-infancy generalized tonic-clonic seizures (a less common feature) yet entirely normal brain MRI at 20 months, demonstrating that the characteristic cerebellar structural anomalies may be absent early in life (PMID: 41769439).

Suggested HPO terms: HP:0001249 (Intellectual disability), HP:0001252 (Hypotonia), HP:0001251 (Ataxia), HP:0001321 (Cerebellar hypoplasia), HP:0000639 (Nystagmus), HP:0000648 (Optic atrophy), HP:0000556 (Retinal dystrophy), HP:0000589 (Coloboma), HP:0000518 (Cataract), HP:0008064 (Ichthyosis), HP:0002650 (Scoliosis), HP:0002808 (Kyphosis), HP:0001250 (Seizure).

Finding 3 — Biochemical signature: extensive serum hypoglycosylation, elevated polyprenol/dolichol ratio, CDG-I transferrin pattern

Patient fibroblasts exhibit a high polyprenol/dolichol ratio with normal dolichol amounts, the biochemical fingerprint of the enzyme defect: "Quantification of dolichol and unreduced polyprenol in the patient's fibroblasts demonstrated a high polyprenol/dolichol ratio with normal amounts of dolichol" (PMID: 22304929). Serum transferrin isoelectric focusing shows a CDG type I pattern, though a caveat exists — up to ~70% of transferrin may be correctly glycosylated in some patients, so screening can be falsely reassuring, and transferrin protein variants can further confound interpretation (as documented in PMM2-CDG, PMID: 37876147).

Quantitative serum N-glycoproteomics reveals the breadth of the defect: "Extensive hypoglycosylation of serum proteins was observed in patients, with 245 of 291 altered glycopeptides decreased in SRD5A3-CDG" (PMID: 41732066), affecting haptoglobin, plasma serine protease inhibitor, alpha-1-B glycoprotein, alpha-2-macroglobulin, ceruloplasmin, and albumin (including at non-canonical sites). Albumin-derived glycopeptides are emerging as diagnostic biomarkers across CDG subtypes including SRD5A3-CDG (PMID: 41713138). Molecular diagnosis is confirmed by exome/genome sequencing with intragenic copy-number analysis, because structural variants occur: "we identified as a second compound heterozygous variant a previously not reported tandem duplication of exons 2-4 in SRD5A3" (PMID: 35339718).

Finding 4 — No disease-modifying therapy; symptomatic management with atorvastatin repurposing under investigation

With ~60 reported cases, treatment is limited to symptomatic/supportive management: developmental therapies, ophthalmologic and orthopedic care, and seizure control. A recent study developed the first high-throughput disease models and reported repurposing of the HMG-CoA reductase inhibitor atorvastatin as an experimental therapeutic strategy: "Approximately 60 cases have been reported, with treatment limited to symptomatic management" (PMID: 41648237). Dietary dolichol supplementation has been proposed conceptually, supported by plant polyprenol-reductase rescue experiments (Finding 5). A broad 2024 CDG treatment overview reinforces that most CDG remain symptomatically managed: "Mostly, we are only able to manage the disease symptoms rather than to address the underlying cause" (PMID: 39236565), while noting that "Innovative therapies, targeting both the root cause and resulting manifestations, have transitioned from the research stage to practical application" for some subtypes (e.g., dietary sugar therapies in MPI-, PGM1-, and PMM2-CDG).

Finding 5 — Evolutionary conservation: plant/yeast models recapitulate the defect and dolichol rescues it

The polyprenol-to-dolichol reduction step is deeply conserved. Arabidopsis thaliana orthologs PPRD1 and PPRD2 encode polyprenol reductases: "which are orthologous to human SRD5A3 (steroid 5α reductase type 3) and encode polyprenol reductases responsible for conversion of polyprenol to dolichol in Arabidopsis thaliana" (PMID: 26628744). PPRD2 deficiency is lethal (male sterility) and is partially rescued by dolichol: "Shortage of dolichol in PPRD2-deficient cells is partially rescued by PPRD1 overexpression or by supplementation with dolichol" (PMID: 26628744), implicating impaired protein glycosylation as the major underlying factor. The conserved dolichol biosynthesis "detour" pathway in budding yeast (PMID: 42201967) provides an additional tractable model system. These conserved systems provide the mechanistic rationale for dietary dolichol supplementation as a conceptual therapeutic avenue.

Finding 6 — Ultrarare disorder with variable expressivity, adult-onset progression, and founder alleles

Fewer than ~60 cases have been reported worldwide, with ~23 distinct variants known by 2022: "So far, only 23 distinct mutations were described" (PMID: 35339718). Inheritance is autosomal recessive with high representation of consanguineous families and population founder alleles (e.g., p.Gln96delinsX in Baluchi/South Asian families). Expressivity is variable even for recurrent alleles: "Homozygosity for the SRDA3 deletion p.Gln96delinsX is not always associated with ocular coloboma" (PMID: 30019980). Comparison of children and adults with SRD5A3 mutations delineated progressive/adult-onset features: "allowing us to delineate the features that may develop over time with this disorder including kyphosis, retinitis pigmentosa, and cataracts" (PMID: 27480077). In the 280-patient FCDGC natural history cohort, dolichol-metabolism disorders (which include SRD5A3-CDG) comprised ~5% of participants (PMID: 38959600).

Finding 7 — Mechanism: dolichol deficiency impairs multiple ER glycosylation pathways

SRD5A3-derived dolichol is required for synthesis of dolichol-linked monosaccharides and the oligosaccharide precursor (Glc3Man9GlcNAc2-PP-dolichol) assembled in the ER during the dolichol cycle: "required for synthesis of dolichol-linked monosaccharides, and the oligosaccharide precursor used for N-glycosylation" (PMID: 20637498). Dolichyl-phosphate (Dol-P) is a rate-limiting intermediate of N-glycosylation and is recycled to the cytoplasmic ER leaflet after cleavage of dolichyl pyrophosphate: "During protein N-glycosylation, dolichyl pyrophosphate (Dol-P-P) is discharged in the lumenal monolayer of the endoplasmic reticulum (ER)" (PMID: 18077451). Because dolichol also anchors glycans in O-/C-mannosylation and GPI-anchor biosynthesis, the deficiency produces a CDG type I biochemical defect (hypoglycosylation of nascent proteins) that branches to impair those pathways as well.

Finding 8 — CDG therapy is largely symptomatic; no established SRD5A3-specific therapy and no isolated mouse disease model

A 2024 overview (Quelhas & Jaeken) confirms that available CDG treatment options remain limited and mostly symptomatic, though targeted root-cause therapies have recently reached practice for some subtypes (PMID: 39236565). For SRD5A3-CDG specifically, no disease-specific therapy is established; atorvastatin repurposing is experimental. A key model-organism gap exists: no isolated Srd5a3-knockout mouse disease model has been characterized — a mouse ~1.2 Mb 5qC3.3 deletion encompassing Srd5a3 caused peri-implantation lethality attributable to Exoc1, not Srd5a3: "deletion of a > 1.2-Mb genomic region containing nine genes (Kit, Kdr, Srd5a3, Tmeme165, Clock, Pdcl2, Nmu, Exoc1, and Cep135)" (PMID: 26346620).

Detailed Section-by-Section Report

1. Disease Information

Overview. SRD5A3-CDG is an autosomal recessive congenital disorder of glycosylation of the dolichol-metabolism subgroup. Dysfunction of polyprenol reductase blocks the terminal step of dolichol synthesis, reducing availability of the LLO precursor required for protein N-glycosylation and impairing other dolichol-dependent glycan pathways, producing a congenital multisystem disorder dominated by neurodevelopmental, cerebellar, ophthalmologic, and cutaneous features.

Key identifiers: - OMIM (disease): #612379 (Congenital disorder of glycosylation, type Iq) - OMIM (allelic): #612713 (Kahrizi syndrome) - OMIM (gene): 611715 (SRD5A3) - Orphanet: ORPHA:79320 (SRD5A3-CDG) - Gene / HGNC: SRD5A3 / HGNC:24420 - Chromosome: 4q12 - Suggested MONDO: MONDO:0012997 (congenital disorder of glycosylation, type Iq) — verify against current MONDO release - ICD-10: E77.8 (other disorders of glycoprotein metabolism); ICD-11: 5C51.1 (disorders of protein glycosylation) — subtype-level codes are not disease-specific - MeSH:* Congenital Disorders of Glycosylation (D018981) — no SRD5A3-specific descriptor

Synonyms / alternative names: SRD5A3-CDG; CDG type Iq (CDG-Iq); steroid 5α-reductase type 3 deficiency; polyprenol reductase deficiency; Kahrizi syndrome (allelic); congenital disorder of glycosylation with intellectual disability, coloboma, cataract and kyphosis.

Information source type. Disease-level knowledge derives predominantly from aggregated disease-level resources (OMIM, Orphanet) and from published individual/small-cohort case reports and case series plus the multicenter FCDGC natural history study — not from large EHR datasets, consistent with ultrarare-disease evidence.

2. Etiology

Causal factors — genetic. SRD5A3-CDG is a monogenic disorder caused by biallelic (homozygous or compound heterozygous) loss-of-function variants in SRD5A3 (PMID: 20637498). There is no environmental or infectious cause.

Genetic risk factors. The only risk factor is inheritance of two pathogenic SRD5A3 alleles. Consanguinity substantially increases risk (many cases arise in consanguineous families), and founder alleles exist in specific populations (e.g., p.Gln96delinsX in Baluchi/South Asian families; PMID: 30019980).

Environmental risk factors / protective factors / gene-environment interactions. Not applicable — as a Mendelian metabolic disorder, no established environmental risk, protective, or gene-environment interaction factors have been reported. No genetic modifier or protective alleles have been defined, though the conserved dolichol "detour"/alternative biosynthesis pathway (PMID: 20637498; PMID: 42201967) likely modulates residual glycosylation capacity and phenotypic severity.

3. Phenotypes

Onset, severity, progression. Most features are congenital or infantile-onset. Severity is variable (mild to severe), and expressivity varies even for identical genotypes (PMID: 30019980). The neurodevelopmental deficit is generally stable/non-degenerative in its cognitive component, while several features are progressive (kyphosis, retinitis pigmentosa, cataracts; PMID: 27480077). Structural cerebellar findings may be absent in the first years despite prominent neurological symptoms (PMID: 41769439).

Quality-of-life impact. No disease-specific EQ-5D/SF-36/PROMIS data exist for SRD5A3-CDG. By extrapolation from CDG cohorts, the combination of intellectual disability, ataxia, and visual impairment causes substantial dependency and impaired daily functioning; the FCDGC cohort found 100% of participants had developmental differences and high burdens of neurologic, GI/liver, and musculoskeletal involvement (PMID: 38959600).

4. Genetic / Molecular Information

Causal gene. SRD5A3 (HGNC:24420; OMIM *611715; chromosome 4q12), encoding polyprenol reductase (UniProt Q9H8P0). Loss of function is the disease mechanism (PMID: 20637498).

Pathogenic variants. Approximately 23 distinct variants were described by 2022 (PMID: 35339718). Reported variant classes include: - Frameshift (e.g., the homozygous frameshift in the original Kahrizi-syndrome family; PMID: 20700148) - Nonsense (e.g., c.57G>A, p.Trp19Ter, ACMG-pathogenic; PMID: 41769439) - Missense (e.g., c.509A>G, p.Tyr170Cys, likely pathogenic; PMID: 41667393) - In-frame deletion/indel founder allele (p.Gln96delinsX; PMID: 30019980) - Intragenic structural variants — a tandem duplication of exons 2–4 (PMID: 35339718)

ACMG/AMP classification. Reported variants are predominantly pathogenic or likely pathogenic, consistent with the broader FCDGC cohort in which most CDG variants were classified pathogenic/likely pathogenic (PMID: 38959600). Allele frequencies in gnomAD are very low (consistent with an ultrarare recessive disorder); founder alleles are enriched in specific populations.

Origin and functional consequence. Variants are germline; there is no somatic component. Functional consequence is loss of function (reduced/absent polyprenol reductase activity → impaired dolichol synthesis).

Modifier genes / epigenetics / chromosomal abnormalities. No established modifier genes or epigenetic mechanisms have been reported. The conserved alternative dolichol biosynthesis pathway is a candidate biological modifier of residual glycosylation (PMID: 20637498; PMID: 42201967). No characteristic large-scale chromosomal abnormalities are associated, though intragenic copy-number changes must be sought (PMID: 35339718).

5. Environmental Information

Not applicable. SRD5A3-CDG is a purely genetic Mendelian disorder. No environmental toxins, lifestyle factors, or infectious agents cause or trigger the disease. (Of note, the DPMS/dolichol-phosphate-mannose pathway is a host dependency factor for flaviviruses such as dengue/Zika PMID: 31915280, but this concerns viral biology, not SRD5A3-CDG etiology.)

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation):

1. Biallelic loss-of-function variants in SRD5A3 reduce/abolish polyprenol reductase activity. (demonstrated; PMID: 20637498)
2. Loss of enzyme activity prevents reduction of the α-isoprene unit of polyprenol, so polyprenol accumulates and dolichol formation is impaired → elevated polyprenol/dolichol ratio in cells. (demonstrated; PMID: 22304929)
3. Reduced dolichol/dolichyl-phosphate limits synthesis of dolichol-linked monosaccharides and the LLO precursor Glc3Man9GlcNAc2-PP-dolichol in the ER (Dol-P is rate-limiting). (demonstrated; PMID: 20637498; PMID: 18077451)
4. Deficient LLO precursor leads to protein N-hypoglycosylation (a CDG type I defect) — extensive across serum glycoproteins. (demonstrated; PMID: 41732066)
5. Branch 4a: Reduced dolichol-anchored glycan donors also impair O-/C-mannosylation and GPI-anchor biosynthesis. (inferred from shared dolichol dependency; PMID: 20637498; PMID: 40902550)
6. Widespread hypoglycosylation disrupts glycoprotein folding, stability, trafficking, and function across many tissues. (inferred; general glycoprotein quality-control biology, PMID: 10794707)
7. Tissue-level dysfunction — most sensitively in developing brain/cerebellum, retina/eye, and skin — results in the clinical phenotype: intellectual disability, hypotonia, cerebellar ataxia/hypoplasia, the ocular spectrum, and ichthyosis. (clinical correlation; PMID: 31638560)
8. Branch 6a (residual pathway): A conserved alternative dolichol biosynthesis pathway supplies residual dolichol, mitigating severity and explaining survival and partial glycosylation. (inferred/demonstrated in models; PMID: 20637498; PMID: 42201967)

ASCII pathway diagram:

 SRD5A3 biallelic LoF
        │ (loss of polyprenol reductase activity)
        ▼
 Polyprenol NOT reduced ──► ↑ polyprenol/dolichol ratio
        │ (dolichol/Dol-P deficient)
        ▼
 ↓ Dolichol-linked monosaccharides + LLO (Glc3Man9GlcNAc2-PP-Dol)  [ER membrane]
        │
        ├──► ↓ N-glycosylation (CDG type I)  ──► serum protein hypoglycosylation
        ├──► ↓ O-/C-mannosylation (branch, inferred)
        └──► ↓ GPI-anchor synthesis (branch, inferred)
                    │
                    ▼
        Glycoprotein misfolding / dysfunction (multi-tissue)
                    │
        ┌───────────┼───────────────┬─────────────┐
        ▼           ▼               ▼             ▼
   Brain/cerebellum  Eye/retina    Skin        Skeleton (progressive)
   ID, hypotonia,    nystagmus,    ichthyosis  kyphosis/scoliosis
   ataxia, hypoplasia optic atrophy,
                     retinal dystrophy,
                     coloboma, cataract

Molecular pathway / cellular process / compartment. The defect is in dolichol biosynthesis feeding the protein N-glycosylation (dolichol) cycle at the ER membrane. Key GO terms: GO:0019408 (dolichol biosynthetic process), GO:0006486 (protein glycosylation), GO:0006487 (protein N-linked glycosylation), GO:0006506 (GPI anchor biosynthetic process), GO:0035269 (protein O-linked mannosylation). Cellular compartment: GO:0005789 (endoplasmic reticulum membrane), GO:0005783 (endoplasmic reticulum). Enzyme activity: polyprenol reductase (EC 1.3.1.94).

Metabolic changes. Isoprenoid/dolichol lipid metabolism is directly disrupted (elevated polyprenol, relatively preserved absolute dolichol via the detour pathway). Immune involvement is not a primary feature of SRD5A3-CDG (unlike immune-relevant CDG such as MOGS-, PGM3-, VPS13B-CDG). Molecular profiling to date is dominated by serum N-glycoproteomics showing broad hypoglycosylation (PMID: 41732066); a GTEx in-silico study noted that tissue vulnerability in CDG does not simply track baseline gene expression (PMID: 42472049).

Cell types (suggested CL terms): cerebellar Purkinje cell (CL:0000121), photoreceptor cell (CL:0000210), keratinocyte (CL:0000312). Suggested CHEBI: polyprenol (CHEBI:26250), dolichol (CHEBI:23514), dolichyl phosphate (Dol-P), dolichyl diphosphate.

7. Anatomical Structures Affected

• Primary organs/systems: central nervous system, especially cerebellum (UBERON:0002037) and cerebrum; eye/retina (UBERON:0000970 / retina UBERON:0000966, optic nerve UBERON:0000941); skin (UBERON:0002097).
• Secondary/progressive involvement: skeleton/spine (kyphosis, scoliosis; vertebral column UBERON:0002415).
• Body systems: nervous, ophthalmic/sensory, integumentary, musculoskeletal.
• Tissue/cell level: neural tissue (cerebellar neurons incl. Purkinje cells), retinal photoreceptors, epidermal keratinocytes.
• Subcellular level: endoplasmic reticulum membrane (site of the dolichol cycle; GO:0005789) is the primary affected compartment.
• Lateralization: manifestations are typically bilateral/generalized (e.g., bilateral nystagmus, bilateral optic atrophy, symmetric cerebellar involvement).

8. Temporal Development

• Onset: Congenital / neonatal-infantile, with hypotonia, nystagmus, and developmental delay evident early; onset pattern is chronic/insidious.
• Progression: The cognitive deficit is broadly static, while specific features are progressive — kyphosis, retinitis pigmentosa, and cataracts develop or worsen over time (PMID: 27480077). Cerebellar structural changes may appear or become detectable later, being absent on early MRI in some infants (PMID: 41769439).
• Course/duration: Chronic, lifelong. No spontaneous remission. Critical period: early childhood neurodevelopment is the key window for supportive/early-intervention therapies; any future disease-modifying therapy would presumably need early initiation.

9. Inheritance and Population

• Epidemiology: Ultrarare; ~60 cases reported worldwide; precise prevalence/incidence are unavailable (well under Orphanet's rare-disease threshold). Dolichol-metabolism disorders were ~5% of the 280-patient FCDGC natural history cohort (PMID: 38959600).
• Inheritance: Autosomal recessive (PMID: 20637498).
• Penetrance: Complete for biallelic LoF (all reported biallelic carriers are affected), with variable expressivity (PMID: 30019980).
• Anticipation / germline mosaicism: Not applicable/not reported (non-repeat-expansion disorder).
• Founder effects / consanguinity: Documented — p.Gln96delinsX founder allele in Baluchi/South Asian families; frequent consanguinity (PMID: 30019980).
• Carrier frequency: Not precisely established; expected very low given rarity.
• Sex ratio: ~1:1 (autosomal); no sex predilection. In the FCDGC cohort overall, sexes were roughly balanced (PMID: 38959600).
• Geographic distribution: Cases reported across diverse populations (European, South Asian, Middle Eastern, Egyptian, etc.); founder alleles create regional clustering.

10. Diagnostics

Recommended approach. Diagnosis is genetic-first in the modern setting: exome or genome sequencing including intragenic copy-number/structural-variant analysis (PMID: 35339718), supported by biochemical screening.

Laboratory / biochemical tests: - Serum transferrin isoelectric focusing / CDT analysis → CDG type I pattern. Caveat: can be falsely reassuring (substantial correctly glycosylated transferrin in some patients) and confounded by transferrin protein variants (PMID: 37876147). - Polyprenol/dolichol ratio in fibroblasts (elevated) — biochemical confirmation of the enzyme defect (PMID: 22304929). - Serum N-glycoproteomics demonstrating extensive hypoglycosylation (PMID: 41732066); albumin glycopeptides as emerging biomarkers (PMID: 41713138).

Imaging / functional / electrophysiology: Brain MRI (cerebellar hypoplasia/atrophy — may be normal early); ophthalmologic evaluation with fundus photography, autofluorescence, and electroretinogram (ERG) for retinal dystrophy (PMID: 41667393).

Genetic testing modalities: WES and WGS are the highest-yield tools; targeted CDG gene panels including SRD5A3; single-gene SRD5A3 testing (incl. deletion/duplication analysis). Karyotyping, FISH, mitochondrial DNA testing, and repeat-expansion testing are not applicable.

Clinical criteria / differential diagnosis. No formal consensus criteria exist; diagnosis rests on the phenotype + CDG-I biochemistry + biallelic SRD5A3 variants. Differential diagnosis includes other CDG type I subtypes (notably PMM2-CDG, the most common), other dolichol-pathway CDG (DHDDS-, DPM1/3-, SRD5A3-), Leber congenital amaurosis/early-onset retinal dystrophies, and cerebellar hypoplasia syndromes; distinguishing features are the specific combination of retinal dystrophy, coloboma/cataract, ichthyosis, and the elevated polyprenol/dolichol ratio.

Screening. No newborn screening exists for SRD5A3-CDG. Carrier and cascade testing are appropriate in known families.

11. Outcome / Prognosis

• Survival/mortality: No formal survival statistics; the disorder is chronic and compatible with survival into adulthood (adult patients are described; PMID: 27480077), consistent with residual glycosylation via the alternative dolichol pathway. Severe early presentations (e.g., seizures) can occur (PMID: 41769439).
• Morbidity/disability: Substantial and lifelong — intellectual disability, ataxia, and progressive visual loss drive major functional impairment and dependency.
• Complications/progression: Progressive kyphosis/scoliosis, retinitis pigmentosa, and cataracts (PMID: 27480077); seizures in a minority.
• Prognostic factors: Genotype (null vs hypomorphic), residual enzyme/dolichol pathway activity, and severity of neurodevelopmental involvement are the main determinants; validated prognostic biomarkers are not established. The Nijmegen Progression CDG Rating Scale (NPCRS) is used across CDG to grade severity (PMID: 38959600).

12. Treatment

No disease-modifying therapy is established. Management is symptomatic and multidisciplinary (PMID: 41648237; PMID: 39236565): - Neurodevelopmental: early intervention, physical/occupational/speech therapy (NCIT: Rehabilitation Therapy). - Ophthalmologic: low-vision support, cataract surgery as indicated (NCIT: Cataract Surgery). - Orthopedic: management of kyphosis/scoliosis. - Seizure control: standard antiseizure medications (e.g., levetiracetam is effective in related CDG; PMID: 37955240) (NCIT: Levetiracetam).

Experimental / investigational: - Atorvastatin repurposing (HMG-CoA reductase inhibitor) — reported as an experimental strategy in newly developed high-throughput SRD5A3-CDG models (PMID: 41648237). NCIT: Atorvastatin Calcium (C29014). - Dietary dolichol supplementation — conceptual, supported by dolichol rescue in plant PPRD2-deficient models (PMID: 26628744). - Cross-CDG precedents for root-cause "sugar" therapies (not yet demonstrated for SRD5A3-CDG): D-galactose in PGM1-CDG (PMID: 41182978), oral mannose in MPI-CDG, and epalrestat (aldose reductase inhibitor) in PMM2-CDG (PMID: 34652821) illustrate the emerging targeted-therapy landscape (PMID: 39236565).

Pharmacogenomics, gene/cell/RNA therapy, immunotherapy, surgery-as-cure: No SRD5A3-specific advanced therapeutics exist; these remain future directions.

13. Prevention

• Primary prevention: Not applicable at the population level (genetic disease). Genetic counseling for at-risk families, carrier testing, and reproductive options (prenatal diagnosis, preimplantation genetic testing) are the principal preventive tools, especially in consanguineous families and founder-allele populations.
• Secondary prevention: No population newborn screen; cascade testing in known families enables early diagnosis and supportive intervention.
• Tertiary prevention: Proactive surveillance and management of progressive complications (vision, spine, seizures) to reduce morbidity.
• Immunization / public-health / environmental interventions: Not applicable.

14. Other Species / Natural Disease

• Taxonomy / orthologs: The polyprenol→dolichol reduction step is deeply conserved. Human SRD5A3 has orthologs in Arabidopsis thaliana (PPRD1, PPRD2; PMID: 26628744) and in budding yeast (Saccharomyces cerevisiae), where the three-step dolichol "detour" pathway is conserved (PMID: 42201967). Mouse ortholog: Srd5a3 (PMID: 26346620).
• Natural/veterinary disease: No naturally occurring SRD5A3-CDG has been reported in companion animals or wildlife (no OMIA entry identified in this investigation).
• Comparative biology: The conservation of the enzyme and the dolichol-rescue phenotype (PPRD2-deficient plants rescued by dolichol) indicates a conserved mechanism linking dolichol supply to protein glycosylation across kingdoms (PMID: 26628744).
• Transmission / zoonosis: Not applicable.

15. Model Organisms

Model limitations. Plant/yeast models capture the enzymatic and glycosylation defect but not the mammalian neuro-ophthalmologic phenotype. The absence of a validated isolated Srd5a3-knockout mouse model is a major gap for preclinical therapeutic testing.

Mechanistic Model / Interpretation

SRD5A3-CDG is best understood as a substrate-supply failure in the dolichol cycle. The single enzymatic lesion (polyprenol reductase deficiency) sits upstream of the entire dolichol-dependent glycosylation machinery. Its immediate, demonstrated consequence is an elevated polyprenol/dolichol ratio — polyprenol accumulates because it cannot be reduced, while absolute dolichol is partly preserved by a conserved alternative/detour biosynthesis pathway. This residual dolichol is mechanistically important: it explains both the survival of patients (versus embryonic lethality expected from total glycosylation failure) and the observation of substantial correctly glycosylated transferrin in some patients.

Downstream, dolichyl-phosphate limitation throttles assembly of the LLO precursor, producing broad protein N-hypoglycosylation (demonstrated by serum glycoproteomics: 245/291 altered glycopeptides decreased). Because dolichol is a shared currency, the defect branches to O-/C-mannosylation and GPI-anchor synthesis (inferred). The tissue selectivity of the clinical phenotype — brain/cerebellum, eye/retina, skin — reflects the particular sensitivity of these developing tissues to glycoprotein dysfunction rather than tissue-specific enzyme expression (GTEx analysis found baseline expression does not predict CDG tissue vulnerability). The temporal profile (congenital onset with later-emerging kyphosis, retinitis pigmentosa, cataracts) suggests both a developmental component (cerebellar hypoplasia, coloboma) and a slowly progressive/degenerative component (retinal, lens, skeletal).

Evidence Base

Evidence source types: The evidence base is predominantly human clinical (case reports, case series, natural history cohort) and in vitro (patient fibroblasts, glycoproteomics), complemented by model-organism work in plants and yeast. There are no large randomized trials, no validated mammalian in-vivo disease model, and no computational/GWAS studies relevant to this Mendelian disorder.

Limitations and Knowledge Gaps

1. Small evidence base. With ~60 cases, all clinical claims derive from case reports/series and one natural history cohort; frequencies are qualitative, and formal prevalence/incidence, survival, and QoL metrics are unavailable.
2. No validated mammalian disease model. The absence of a characterized isolated Srd5a3-knockout mouse (PMID: 26346620) hampers mechanistic and preclinical therapeutic studies.
3. Branch mechanisms inferred. Impairment of O-/C-mannosylation and GPI-anchor synthesis is inferred from shared dolichol dependency rather than directly demonstrated in SRD5A3-CDG patients.
4. Diagnostic pitfalls. Transferrin-based screening can be falsely reassuring; intragenic CNVs require dedicated analysis — both risk under-/mis-diagnosis.
5. No proven therapy. Atorvastatin repurposing and dolichol supplementation are experimental; no clinical efficacy data exist for SRD5A3-CDG.
6. Genotype–phenotype correlation is weak. Variable expressivity (even for identical alleles) is unexplained; modifier genes and the quantitative contribution of the alternative dolichol pathway are undefined.

Proposed Follow-up Experiments / Actions

1. Generate a conditional/tissue-specific Srd5a3 mouse model (e.g., neural- and eye-restricted knockouts) to overcome the peri-implantation lethality confounded by Exoc1, enabling phenotype recapitulation and therapeutic testing.
2. Validate atorvastatin efficacy in patient-derived models (iPSC-derived neurons/organoids, cerebellar and retinal organoids) and, if positive, design an n-of-few clinical trial with glycosylation biomarkers as endpoints (PMID: 41648237).
3. Test dietary dolichol supplementation rescue in mammalian patient-derived systems, building on plant/yeast rescue data (PMID: 26628744).
4. Directly quantify O-/C-mannosylation and GPI-anchor defects in patient cells to confirm the inferred mechanistic branches.
5. Standardize diagnostics: adopt reflex confirmatory testing (polyprenol/dolichol ratio, glycoproteomics, CNV analysis) whenever transferrin screening is normal but clinical suspicion is high; evaluate albumin glycopeptides as a robust biomarker (PMID: 41713138).
6. Enroll SRD5A3-CDG patients in the FCDGC natural history study to build prospective longitudinal outcome, NPCRS severity, and QoL data (PMID: 38959600).
7. Map founder alleles and carrier frequencies in high-consanguinity populations to guide carrier screening and reproductive counseling.

Report compiled from 8 confirmed findings across 35 reviewed publications. Evidence is predominantly human-clinical and in-vitro, supplemented by conserved plant/yeast models. All mechanistic and clinical claims are cited to primary literature by PMID; inferred steps are explicitly labeled.